{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-036822","form_type":"8-K","ticker":"RAPP","cik":"0002012593","company_name":"Rapport Therapeutics, Inc.","filed_at":"2025-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.796335+00:00","generated_at":"2026-05-25T00:13:22.011718+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Rapport Therapeutics FY2024 net loss $78.3M; RAP-219 epilepsy trial top line Q3 2025","bullets":["Net loss $78.3M for FY2024 vs $34.8M in FY2023; R&D expense $60.9M up from $28.0M.","Phase 2a trial of RAP-219 in refractory focal epilepsy topline results expected Q3 2025 (narrowed timeline).","Appointed Jeffrey Sevigny, M.D., as chief medical officer, effective immediately.","Cash and investments $305.3M at year-end; expected to fund operations through end of 2026.","FDA placed IND for Phase 2a DPNP trial on clinical hold; company finalizing trial plans."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-036822","json":"https://secwatch.observer/filing/0000950170-25-036822.json","markdown":"https://secwatch.observer/filing/0000950170-25-036822.md","text":"https://secwatch.observer/filing/0000950170-25-036822.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/0000950170-25-036822-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025036822/rapp-20250311.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T00:13:22.011718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}